5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | NEUTRAL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 6.94▲ | 6.95▲ | 6.95▲ | 7.19▼ | 8.40▼ |
MA10 | 6.94▲ | 6.94▲ | 6.95▲ | 7.76▼ | 8.52▼ |
MA20 | 6.94▲ | 6.96▲ | 7.01▼ | 8.79▼ | 7.61▼ |
MA50 | 6.94▲ | 7.10▼ | 7.45▼ | 8.43▼ | 9.85▼ |
MA100 | 6.95▲ | 7.49▼ | 8.41▼ | 7.58▼ | 7.69▼ |
MA200 | 7.02▼ | 8.53▼ | 8.71▼ | 9.30▼ | 5.71▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.001▼ | 0.015▲ | 0.027▲ | -0.306▼ | 0.049▲ |
RSI | 55.201▲ | 44.187▼ | 38.667▼ | 29.670▼ | 42.990▼ |
STOCH | 33.333 | 63.503 | 36.124 | 7.878▼ | 51.646 |
WILL %R | -16.667▲ | -53.571 | -59.375 | -96.394▼ | -83.468▼ |
CCI | 61.053 | 32.768 | -42.397 | -88.236 | -82.874 |
Friday, September 12, 2025 01:01 PM
According to Benzinga Pro, WAVE Life Sciences's peer group average for short interest as a percentage of float is 14.80%, which means the company has less short interest than most of its peers. Did ...
|
Wednesday, September 10, 2025 01:42 PM
Wave Life Sciences (WVE) recently announced positive results from its Phase 1b/2a RestorAATion-2 study of WVE-006, showing favorable safety and promising clinical implications in treating alpha-1 ...
|
Monday, September 08, 2025 08:11 AM
Detailed price information for Wave Life Sci Ord Sh (WVE-Q) from The Globe and Mail including charting and trades.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/09/25 | 6.99 | 7.06 | 6.835 | 6.965 | 1,030,086 |
12/09/25 | 7.15 | 7.18 | 6.95 | 6.97 | 1,852,300 |
11/09/25 | 7.32 | 7.3554 | 6.974 | 7.16 | 2,264,792 |
10/09/25 | 7.52 | 7.7609 | 7.27 | 7.39 | 2,309,456 |
09/09/25 | 7.55 | 7.64 | 7.37 | 7.48 | 1,524,208 |
08/09/25 | 8.26 | 8.2999 | 7.50 | 7.58 | 2,663,709 |
05/09/25 | 8.23 | 8.61 | 8.1001 | 8.29 | 2,782,084 |
04/09/25 | 8.00 | 8.195 | 7.49 | 8.18 | 3,322,679 |
03/09/25 | 7.41 | 8.00 | 7.115 | 8.00 | 10,839,358 |
02/09/25 | 9.48 | 9.869 | 9.41 | 9.62 | 1,130,647 |
|
|
||||
|
|
||||
|
|